Author: kodiac

  • Histrelin

    Synthetic gonadotropin-releasing hormone superagonist nonapeptide with sustained pituitary-gonadal axis suppression through GnRH receptor desensitization and downregulation

    A synthetic nonapeptide analog of endogenous gonadotropin-releasing hormone bearing a D-histidine(N-benzyl) substitution at position 6 and an ethylamide C-terminal modification, conferring approximately 100- to 200-fold greater potency than native GnRH and marked resistance to enzymatic degradation, developed at Ortho Pharmaceutical in the early 1980s and now FDA-approved as a once-yearly subcutaneous hydrogel implant for advanced prostate cancer (Vantas, approved 2004, discontinued 2020) and central precocious puberty (Supprelin LA, approved 2007), distinguished from other GnRH agonists by the highest binding affinity in the clinical class and the longest approved dosing interval achieved through a diffusion-controlled hydrogel polymer reservoir delivery system.

    Abstract

    Histrelin (pGlu-His-Trp-Ser-Tyr-D-His(Bzl)-Leu-Arg-Pro-NHEt; CAS 76712-82-8, free base; molecular formula C66H86N18O12; molecular weight 1323.53) is a synthetic nonapeptide analog of the hypothalamic decapeptide gonadotropin-releasing hormone (GnRH, also designated luteinizing hormone-releasing hormone, LHRH) distinguished from other members of the clinical GnRH agonist class by exceptionally high receptor binding affinity and by a unique formulation as a once-yearly subcutaneous hydrogel polymer implant [1, 2]. The compound incorporates two structural modifications to native GnRH that collectively confer superagonist potency and metabolic stability: replacement of glycine at position 6 with D-histidine bearing an N-benzyl substituent on the imidazole ring, which eliminates the principal endopeptidase cleavage site and introduces a bulky aromatic moiety favorable to hydrophobic interaction with the GnRH receptor transmembrane domain; and replacement of the C-terminal glycinamide (position 10) with an ethylamide, which further resists carboxypeptidase degradation [3, 4]. The resulting peptide binds the type I GnRH receptor with affinity approximately 100- to 200-fold greater than native GnRH and produces the characteristic biphasic pharmacological response common to all GnRH superagonists [5, 6]. Acute administration stimulates pituitary gonadotroph secretion of luteinizing hormone and follicle-stimulating hormone, producing transient elevations in gonadal steroid output (the “flare” phase, lasting 7 to 14 days). Chronic continuous administration produces homologous desensitization of the GnRH receptor through receptor internalization, uncoupling from Gq/11-phospholipase C signaling, and transcriptional downregulation of GnRH receptor expression, resulting in profound and sustained suppression of gonadotropin secretion and a hypogonadal state equivalent to surgical castration in both sexes [5, 6, 7]. Histrelin was initially developed at Ortho Pharmaceutical Corporation (a Johnson and Johnson subsidiary) in the early 1980s and studied in daily subcutaneous injection formulations for central precocious puberty, prostate cancer, and endometriosis [8, 9]. The compound was subsequently reformulated by Roberts Laboratories (later acquired by Shire Pharmaceuticals, then Endo Pharmaceuticals) into a diffusion-controlled hydrogel polymer reservoir subcutaneous implant delivering approximately 65 micrograms of histrelin acetate per day over 12 months [10, 11]. This implant technology produced two FDA-approved products: Vantas (50 mg histrelin acetate implant for palliative treatment of advanced prostate cancer, approved October 2004) and Supprelin LA (50 mg histrelin acetate implant for central precocious puberty, approved May 2007) [12, 13]. Vantas was discontinued in 2020 owing to manufacturing quality issues at the production facility; Supprelin LA remains commercially available. Pharmacokinetics of the implant formulation are characterized by sustained zero-order drug release producing median steady-state serum histrelin concentrations of approximately 0.2 to 0.4 ng/mL, with a terminal elimination half-life of the released peptide of approximately 4 hours, 92 percent subcutaneous bioavailability, and approximately 70 percent plasma protein binding [10, 14]. Metabolism is hepatic through peptidase-mediated degradation. The adverse-event profile is dominated by the pharmacological consequences of gonadal steroid suppression: hot flashes, reduced libido, erectile dysfunction or amenorrhea, and long-term bone mineral density reduction. Implant site reactions (bruising, pain, erythema) occur in approximately 50 percent of recipients. The initial flare phase carries specific risk in metastatic prostate cancer, which is mitigated by co-administration of an antiandrogen during the first 2 to 4 weeks of therapy. Postmarketing surveillance has identified rare but serious adverse events including pseudotumor cerebri, seizures, psychiatric symptoms (emotional lability, depression, suicidal ideation), and severe cutaneous adverse reactions. This monograph reviews the chemistry and synthesis, the biphasic GnRH receptor pharmacology, the comprehensive human pharmacokinetic record, the clinical evidence base across prostate cancer, central precocious puberty, endometriosis, and gender-affirming therapy indications, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five GnRH agonist candidates against histrelin on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1397Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Teduglutide

    Dipeptidyl peptidase-IV-resistant glucagon-like peptide-2 analog and GLP-2 receptor agonist

    A recombinant 33-amino-acid analog of human glucagon-like peptide-2 bearing a single glycine-for-alanine substitution at position 2 that confers resistance to dipeptidyl peptidase-IV degradation, developed by NPS Pharmaceuticals and approved for the treatment of short bowel syndrome with intestinal failure in adults and pediatric patients dependent on parenteral support.

    Abstract

    Teduglutide is a recombinant analog of human glucagon-like peptide-2 (GLP-2) and the first GLP-2 receptor agonist approved for clinical use in the treatment of short bowel syndrome associated with intestinal failure (SBS-IF). The compound differs from native human GLP-2 by a single amino acid substitution: glycine replaces alanine at position 2 from the N-terminus, eliminating the dipeptidyl peptidase-IV (DPP-IV) cleavage site and extending the plasma elimination half-life from approximately 7 minutes (native GLP-2) to approximately 2 to 3 hours after subcutaneous administration [1, 2]. This modification preserves full agonist activity at the GLP-2 receptor (GLP-2R), a class B G-protein-coupled receptor expressed on intestinal subepithelial myofibroblasts, enteric neurons, and enteroendocrine cells, while enabling once-daily subcutaneous dosing at 0.05 mg/kg body weight.

    The intestinotrophic actions of teduglutide are mediated through GLP-2R activation on subepithelial myofibroblasts, which triggers downstream release of insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), and keratinocyte growth factor (KGF) [3, 4]. These paracrine mediators drive crypt cell proliferation, inhibit enterocyte apoptosis, increase villus height, enhance mucosal barrier function, slow gastric emptying, reduce gastric acid secretion, and increase mesenteric blood flow [5]. The composite physiological effect is an expansion of absorptive intestinal surface area and an improvement in the efficiency of fluid and nutrient absorption in patients with shortened bowel.

    Clinical development centered on the pivotal Phase 3 STEPS trial (Study of Teduglutide Effectiveness in Parenteral Nutrition-Dependent Short-Bowel Syndrome Subjects), in which 86 adult SBS-IF patients were randomized to teduglutide 0.05 mg/kg/day or placebo for 24 weeks [6]. The primary endpoint (20 to 100 percent reduction in parenteral support volume at weeks 20 and 24) was met by 63 percent of teduglutide-treated patients compared to 30 percent of placebo-treated patients (P = 0.002). Three teduglutide-treated patients achieved complete enteral autonomy (full independence from parenteral support). Long-term extension studies (STEPS-2, STEPS-3) demonstrated sustained reductions in parenteral support requirements over 30 months or more, with additional patients achieving enteral autonomy on continued treatment [7, 8].

    Teduglutide received European Commission marketing authorization as Revestive in August 2012, United States Food and Drug Administration (FDA) approval as Gattex in December 2012 for adult SBS-IF patients dependent on parenteral support, and FDA pediatric indication expansion in May 2019 for patients one year of age and older [9, 10]. The compound was developed by NPS Pharmaceuticals (subsequently acquired by Shire, then Takeda), with Takeda holding global commercial rights.

    The principal safety concerns are the trophic effects of sustained GLP-2R stimulation on intestinal epithelium. Colorectal polyps have been reported in clinical trials and postmarketing surveillance at rates higher than placebo, necessitating colonoscopy within 6 months before treatment initiation, after 1 year of treatment, and every 5 years thereafter [11]. Intestinal obstruction, biliary and pancreatic disease, and fluid overload from increased intestinal absorption are additional monitored risks. Common adverse events at the approved dose include abdominal pain (28 percent), nausea (26 percent), injection site reactions (26 percent), abdominal distension (17 percent), and headache (16 percent) [12].

    This monograph reviews the chemistry, amino acid sequence, and DPP-IV resistance mechanism of teduglutide; the discovery of GLP-2 as an intestinotrophic factor and the development trajectory from preclinical demonstration through registration; the molecular pharmacology of GLP-2R signaling and downstream trophic mediators; the pharmacokinetic profile including absorption, distribution, metabolism, and elimination; the preclinical evidence in rodent models of SBS, mucositis, and colitis; the clinical evidence base across the STEPS trial series and pediatric studies; sourcing and quality verification considerations; reconstitution and handling; stack interaction considerations including effects on oral medication absorption; the adverse event and safety profile with emphasis on colorectal polyp risk; and a comparative assessment of five alternative GLP-2R agonists or intestinal trophic agents (glepaglutide, apraglutide, native GLP-2, growth hormone with glutamine, and somatropin) against teduglutide on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1415Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • SS-20

    Mitochondria-targeted cardiolipin-binding tetrapeptide without intrinsic radical-scavenging activity

    A synthetic Szeto-Schiller tetrapeptide (Phe-D-Arg-Phe-Lys-NH2) that selectively concentrates on the inner mitochondrial membrane through electrostatic and hydrophobic interactions with cardiolipin, restoring electron transport chain coupling efficiency and ATP synthesis under ischemic, oxidative, and age-related stress without direct free-radical scavenging, thereby dissociating mitochondrial protection from antioxidant chemistry and establishing cardiolipin modulation as the operative therapeutic mechanism of the SS peptide class.

    Abstract

    SS-20 (SBT-20; H-Phe-D-Arg-Phe-Lys-NH2; CAS 736992-19-1; molecular weight 595.75; molecular formula C30H45N9O4) is a cell-permeable, mitochondria-targeted synthetic tetrapeptide of the Szeto-Schiller (SS) class, developed at the Department of Pharmacology at Weill Cornell Medical College by Hazel H. Szeto and colleagues as a structural analog of SS-31 (elamipretide) that retains mitochondrial targeting and cardiolipin binding but lacks the 2′,6′-dimethyltyrosine (Dmt) residue responsible for intrinsic reactive oxygen species scavenging in SS-31 [1, 2]. The deliberate substitution of phenylalanine for Dmt at position 1 eliminates the phenolic hydroxyl group that confers direct radical-scavenging capacity, making SS-20 an indispensable mechanistic control compound that has proven essential for establishing that cardiolipin interaction, rather than antioxidant chemistry, is the operative therapeutic mechanism of the SS peptide class [3, 4]. SS-20 carries a net 3+ charge at physiological pH and concentrates approximately 1000-fold on the inner mitochondrial membrane (IMM), where it binds the tetra-acyl dianion cardiolipin through electrostatic interactions between its basic residues (D-Arg, Lys) and the cardiolipin phosphate head groups, with its aromatic phenylalanine residues inserting into the hydrophobic acyl chain region [5, 6]. This binding modulates the interaction between cardiolipin and cytochrome c, promoting the electron carrier function of cytochrome c over its peroxidase activity, thereby improving mitochondrial electron transport chain coupling efficiency, increasing ATP synthesis per unit oxygen consumed, and reducing mitochondrial reactive oxygen species generation as a downstream consequence of improved coupling rather than through direct scavenging [3, 4]. In preclinical models, SS-20 has demonstrated efficacy comparable to SS-31 in protecting against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mice at 4 mg/kg intraperitoneal, with complete preservation of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra pars compacta and 40 percent attenuation of striatal dopamine depletion [7]. In renal ischemia-reperfusion models, pretreatment with SS-20 extended warm ischemia tolerance in rat kidneys from 30 to 45 minutes, preserved cristae architecture on electron microscopy, restored tissue ATP levels, and reduced apoptosis, cytoskeletal breakdown, and interstitial fibrosis [8]. In cardiac ischemia-reperfusion, intravenous SS-20 (SBT-20) at 0.3 and 3.0 mg/kg/hour reduced myocardial infarct size by 20 percent relative to saline control in a rat coronary occlusion model, outperforming the reported 11 percent reduction achieved by elamipretide (MTP-131) in comparable protocols [9]. In pressure-overload heart failure induced by transverse aortic constriction (TAC) in mice, SS-20 produced partial but significant attenuation of cardiac hypertrophy and improvement in fractional shortening, with preferential protection of actin cytoskeletal pathways over mitochondrial and metabolic pathways in global proteomic analysis, a pattern distinct from the broader mitochondrial proteomic protection provided by SS-31 [10]. In chronic renal failure induced by 5/6 nephrectomy in mice, SBT-20 at 5 mg/kg intraperitoneal reduced inflammatory cytokines (interleukin-1-beta, interleukin-6, tumor necrosis factor alpha), normalized NF-kappaB signaling, restored mitochondrial membrane potential, and improved serum creatinine, blood urea nitrogen, and creatinine clearance [11]. The compound has not entered human clinical trials; all pharmacological characterization is preclinical. SS-20 is not approved by any regulatory authority for any indication. It is supplied as a research-grade synthetic peptide by multiple chemical suppliers at greater than 98 percent purity by high-performance liquid chromatography and is used principally as a mechanistic tool to dissect the relative contributions of cardiolipin binding and antioxidant activity within the SS peptide class, and as a candidate therapeutic lead for ischemia-reperfusion injury, neurodegenerative disease, and chronic kidney disease in settings where direct radical scavenging may not be the desired pharmacological intervention.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1388Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Somatrogon

    Long-acting recombinant human growth hormone receptor agonist (CTP-modified growth hormone fusion protein)

    A long-acting glycoprotein fusion of recombinant human growth hormone with three copies of the C-terminal peptide of human chorionic gonadotropin beta-subunit, engineered by OPKO Health and commercialized by Pfizer as a once-weekly subcutaneous injection for the treatment of pediatric growth hormone deficiency, distinguished from daily somatropin by its prolonged pharmacokinetic profile and from other long-acting growth hormone preparations by its CTP-based half-life extension platform.

    Abstract

    Somatrogon (somatrogon-ghla; CAS 1663481-09-1; approximate molecular weight 40 kDa including glycosylation) is a long-acting recombinant human growth hormone receptor agonist produced in Chinese hamster ovary cells by recombinant DNA technology and approved for the treatment of pediatric growth hormone deficiency as a once-weekly subcutaneous injection. The molecule comprises the complete 191-amino-acid sequence of native human growth hormone with one copy of the 28-amino-acid C-terminal peptide (CTP) from the beta-subunit of human chorionic gonadotropin fused at the N-terminus and two tandem copies of CTP fused at the C-terminus [1, 2]. The CTP cassettes introduce O-linked glycosylation sites that reduce renal clearance, extend the circulating half-life from the 2 to 4 hours of native somatropin to an effective half-life of approximately 28 to 38 hours, and thereby permit once-weekly dosing at 0.66 mg/kg without loss of growth-promoting efficacy relative to daily somatropin [3, 4]. Somatrogon binds the homodimeric growth hormone receptor and activates the JAK2-STAT5b signaling cascade, producing downstream increases in hepatic and peripheral insulin-like growth factor 1 (IGF-1) synthesis, skeletal longitudinal growth, protein anabolism, and modulation of carbohydrate and lipid metabolism identical in pathway to native growth hormone [5, 6]. The pivotal global Phase 3 clinical trial (NCT02968004) randomized 224 treatment-naive prepubertal children with growth hormone deficiency to once-weekly somatrogon (0.66 mg/kg) or once-daily somatropin (Genotropin, 0.24 mg/kg/week) for 12 months and demonstrated non-inferiority of somatrogon on the primary endpoint of annualized height velocity (somatrogon 10.12 cm/year versus somatropin 9.78 cm/year), with height standard deviation score improvements numerically favoring the somatrogon arm [7]. A parallel Phase 3 study in Japanese children confirmed non-inferiority with consistent safety [8]. Long-term extension data through 5 years of treatment demonstrated sustained catch-up growth with a mean height standard deviation score increase from baseline of 1.94 at extension year 4, consistent with durable efficacy [9]. The safety profile is characterized by injection site reactions (pain in 39.4 percent of somatrogon recipients versus 25.2 percent of somatropin recipients), nasopharyngitis, headache, pyrexia, and the pharmacological class effects of growth hormone therapy including transient hyperglycemia, hypothyroidism unmasking, and benign intracranial hypertension [7, 10]. Immunogenicity is notable: 77.1 percent of somatrogon-treated subjects developed anti-drug antibodies during the 12-month pivotal trial versus 15.6 percent of somatropin-treated subjects, but neutralizing antibody activity was not detected, and anti-drug antibodies did not have a clinically significant impact on efficacy or safety through 42 months of observation [7, 11]. Somatrogon received marketing authorization from the European Medicines Agency in January 2022, from Health Canada in December 2021, from the Australian Therapeutic Goods Administration in 2021, and from the United States Food and Drug Administration on June 27, 2023, following an initial complete response letter in January 2022 that required supplementary manufacturing data [12, 13]. The compound is marketed as Ngenla in a prefilled pen presentation requiring no reconstitution. This monograph reviews the molecular design, CTP-based half-life extension technology, growth hormone receptor pharmacology, comprehensive pharmacokinetic characterization, the pediatric clinical evidence base, sourcing and handling considerations, drug interaction profile, adverse event and immunogenicity data, and a structured comparative assessment of five alternative growth hormone preparations against somatrogon on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1383Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pemvidutide

    Balanced dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist peptide with glycolipid half-life extension

    A 29-amino-acid unimolecular peptide engineered for equipotent GLP-1 and glucagon receptor co-agonism, conjugated to a proprietary glycolipid moiety for weekly subcutaneous dosing, under clinical development for metabolic dysfunction-associated steatohepatitis, obesity, and alcohol use disorder.

    Abstract

    Pemvidutide (ALT-801; CAS 2538014-94-5; UNII A35F525WBG; molecular formula C182H275N39O54; molecular weight 3873.42 g/mol) is a synthetic 29-amino-acid peptide that functions as a balanced (1:1) dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), developed by Altimmune, Inc. (Gaithersburg, Maryland) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The compound incorporates sequence elements derived from both GLP-1 and glucagon and is conjugated to an 18-carbon diacid alkyl chain through a proprietary glycosidic linkage (designated EuPort), which provides near-quantitative but transient binding to serum albumin and extends the plasma half-life to a duration consistent with once-weekly subcutaneous administration without dose titration [1, 2]. The dual receptor mechanism differentiates pemvidutide from selective GLP-1 receptor agonists such as semaglutide and liraglutide: GLP-1R activation suppresses appetite through hypothalamic and brainstem satiety circuits, delays gastric emptying, and improves glycemic control, while GCGR activation directly stimulates hepatic fatty acid beta-oxidation, suppresses de novo lipogenesis, and increases energy expenditure through thermogenic pathways, producing a composite antisteatotic and weight-reducing pharmacology that is mechanistically suited to liver-predominant metabolic disease [3, 4, 5]. In the translational AMLN diet-induced obese mouse model of NASH, pemvidutide at 10 nmol/kg subcutaneous produced approximately 25 percent body weight reduction, significant reductions in liver triglycerides, galectin-3, collagen type 1 alpha 1, and NAFLD Activity Score, with efficacy exceeding that of semaglutide and elafibranor at equimolar doses on composite histological endpoints [6]. Clinical development has advanced through Phase 1 studies (NCT04561245, 100 subjects), Phase 1b/2a studies in MASLD (NCT05006885, 95 subjects; NCT05292911, 64 subjects), the Phase 2 MOMENTUM obesity trial (391 subjects, 48 weeks), and the Phase 2b IMPACT trial in biopsy-confirmed MASH (NCT05989711, 212 subjects) [1, 7, 8, 9, 10]. In the Phase 1b/2a MASLD study (Harrison et al. 2025), 12 weeks of pemvidutide at 1.8 mg weekly produced a 68.5 percent relative reduction in liver fat content by MRI-proton density fat fraction versus 4.4 percent for placebo (p < 0.001), with 55.6 percent of treated subjects achieving liver fat normalization to 5 percent or below [8]. Extension to 24 weeks produced 75.2 percent liver fat reduction at 1.8 mg and 6.2 percent body weight reduction versus placebo [7]. In the MOMENTUM trial, pemvidutide at 2.4 mg weekly for 48 weeks produced mean weight loss of 15.6 percent versus 2.2 percent on placebo, with body composition analysis demonstrating 78.1 percent of weight loss attributable to fat mass and 21.9 percent to lean mass [9, 10]. In the Phase 2b IMPACT trial (Noureddin et al. 2025) in 212 patients with biopsy-confirmed MASH and fibrosis stages F2 or F3, pemvidutide met the primary endpoint of MASH resolution without fibrosis worsening: 59.1 percent at 1.2 mg and 52.1 percent at 1.8 mg versus 19.1 percent for placebo (p < 0.0001 for both comparisons) [11]. Topline 48-week data demonstrated continued antifibrotic activity with statistically significant improvements in Enhanced Liver Fibrosis score and liver stiffness measurement versus placebo [12]. The United States Food and Drug Administration has granted Breakthrough Therapy Designation for pemvidutide in MASH (January 2026) and Fast Track designations for both MASH and AUD [13, 14]. Phase 3 registrational programs for MASH and the VELOCITY Phase 3 program for obesity are in planning as of May 2026. Safety across completed trials has been favorable; adverse events are predominantly gastrointestinal (nausea, diarrhea, decreased appetite), mild to moderate in severity, and concentrated in the first 16 weeks of treatment. No imbalances in cardiac events, arrhythmias, or clinically meaningful heart rate increases have been observed. This monograph reviews the compound identification, structural pharmacology, mechanism of action, pharmacokinetics, preclinical and clinical evidence base, sourcing and quality verification, reconstitution and handling, stack interactions, adverse events, and a comparative assessment of five alternative agents (survodutide, semaglutide, tirzepatide, cotadutide, resmetirom) against pemvidutide on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1410Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pancragen

    Synthetic tetrapeptide bioregulator of pancreatic endocrine and exocrine cell differentiation and function

    A synthetic tetrapeptide (Lys-Glu-Asp-Trp) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as a tissue-specific epigenetic modulator of pancreatic cell differentiation, glucose homeostasis, and beta cell functional recovery in aging and type 2 diabetes mellitus.

    Abstract

    Pancragen (Lys-Glu-Asp-Trp-NH2; KEDW) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology (Russia) as a tissue-specific modulator of pancreatic endocrine and exocrine cell differentiation and function. The compound belongs to the Khavinson class of ultrashort (two to four amino acid) bioregulatory peptides, a pharmacological category defined by the hypothesis that short peptides penetrate cell nuclei, bind complementary DNA sequences in promoter regions through electrostatic and hydrogen-bond interactions, and modulate gene expression in a tissue-specific manner without engaging classical cell-surface receptors. Pancragen was derived from fractionation of bovine pancreatic tissue extracts; the tetrapeptide Lys-Glu-Asp-Trp was identified as the minimal active sequence responsible for the pancreotrophic activity of the parent extract preparation Suprefort. The compound has a molecular formula of C26H36N6O9 (free acid form) and a molecular weight of 576.60 g/mol. Physical-chemical characterization by ultraviolet-visible absorption spectroscopy, circular dichroism, and molecular modeling has demonstrated that the KEDW tetrapeptide binds double-stranded DNA in the major groove at sequences containing the ACCT motif, which is found in promoter regions of genes responsible for pancreatic cell differentiation and function [1]. The principal downstream molecular consequence of this interaction is upregulation of transcription factors that govern pancreatic endocrine cell fate, including PDX1 (the earliest marker of pancreatic progenitor cells and the master regulator of beta cell identity), NGN3, PAX6, PAX4, FOXA2, NKX2-2, and NKX6.1 [2, 3]. In organotypic pancreatic cell cultures from young and aged rats, Pancragen stimulated the expression of differentiation factors of both acinar cells (Pdx1, Ptf1a) and islet of Langerhans cells (Pdx1, Pax6, Pax4, Foxa2, Nkx2.2), with the inducing effect more pronounced in aged cultures, consistent with a geroprotective mechanism [3]. Preclinical pharmacology in streptozotocin-induced diabetic rats demonstrated that oral Pancragen produced a pronounced hypoglycemic effect during the treatment period and that intramuscular administration normalized the adhesion properties of mesenteric capillary endothelium without modifying capillary permeability, suggesting homeostatic and endothelioprotective activity in early diabetes [4]. In a study of biological activity using immunoenzyme and high-performance liquid chromatography methods, the tetrapeptide modulated metabolic parameters characterizing apoptosis, including caspase-3 activity, in pancreatic beta cells and hepatocytes from streptozotocin-treated animals [5]. Primate studies in aged female rhesus monkeys demonstrated that a 10-day intramuscular course of Pancragen at 50 micrograms per day markedly increased the glucose disappearance rate, decreased basal insulin and C-peptide levels, and normalized glucose, insulin, and C-peptide dynamics during intravenous glucose tolerance testing, with partial persistence of these effects for three weeks after cessation of treatment [6, 7]. A comparative study in the same primate model demonstrated that Pancragen normalized insulin and C-peptide levels (suggesting recovery of disturbed glucose tolerance) while glimepiride produced a stronger but delayed blood-glucose-lowering effect without substantially affecting insulin secretion, indicating mechanistically distinct activity [7]. In a clinical study of 33 elderly patients with type 2 diabetes mellitus, Pancragen administered against a background of constant-dose glibenclamide significantly decreased fasting plasma glucose and glucose concentrations at two hours during oral glucose tolerance testing, reduced plasma insulin levels, and decreased the HOMA insulin resistance index; an additional glucose-lowering effect persisted for two weeks after cessation of Pancragen in 60 percent of patients who continued glibenclamide at unchanged doses [8]. Organotypic tissue culture studies confirmed that Pancragen at concentrations as low as 0.05 ng/mL stimulated tissue growth in pancreatic explants from both young and aged rats, with the stimulating effect tissue-specific (no effect on non-pancreatic tissue explants at the same concentration) [9]. The compound has not been approved by the United States Food and Drug Administration, the European Medicines Agency, or any major Western regulatory authority. It is marketed in Russia as a dietary supplement (Pancragen capsules) and is available internationally as a research-grade peptide from multiple suppliers. Formal toxicology studies meeting International Council for Harmonisation or FDA regulatory standards have not been published. The existing safety data, derived exclusively from the Khavinson research network, report no significant adverse events in preclinical or clinical studies at the doses and durations studied. This monograph reviews the chemistry, synthesis, and structural class of Pancragen; the epigenetic and transcriptional mechanism of action; the available pharmacokinetic considerations for ultrashort peptides; the preclinical pharmacology in cell culture, rodent, and primate models; the clinical evidence base in type 2 diabetes; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signals; and a comparative assessment of five alternative pancreatic bioregulatory or beta cell-active compounds against Pancragen on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1403Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Octreotide

    Synthetic cyclic octapeptide somatostatin analog with preferential binding to somatostatin receptor subtypes 2 and 5

    A disulfide-bridged octapeptide analog of hypothalamic somatostatin-14 developed at Sandoz as SMS 201-995, distinguished from the native hormone by a 30-fold increase in inhibition of growth hormone release relative to insulin suppression and an elimination half-life extended from under 3 minutes to approximately 100 minutes after subcutaneous administration.

    Abstract

    Octreotide (SMS 201-995) is a synthetic cyclic octapeptide analog of somatostatin-14 that reproduces the pharmacologically essential tetrapeptide core (Phe-Trp-Lys-Thr) of the native hormone within a conformationally constrained disulfide-bridged ring, yielding a compound with high-affinity binding at somatostatin receptor subtype 2 (SSTR2; Ki approximately 0.4 to 0.6 nanomolar), moderate affinity at SSTR5 (Ki approximately 7 nanomolar) and SSTR3 (Ki approximately 35 nanomolar), and negligible affinity at SSTR1 and SSTR4 [1, 2]. The compound was synthesized at the Sandoz Forschungsinstitut in Basel by Bauer, Briner, Doepfner, and colleagues in 1982, selected from a series of conformationally stabilized somatostatin fragments on the basis of a 45-fold increase in potency for growth hormone inhibition relative to somatostatin-14 in an in vitro rat pituitary bioassay and a 30-fold selectivity for growth hormone suppression over insulin suppression, a therapeutic index absent from the native tetradecapeptide [1]. The critical structural innovation was the introduction of a D-Trp at position 4 and D-phenylalanol at the C-terminus within a cystine-bridged octapeptide ring that resisted enzymatic degradation and extended the plasma elimination half-life from the approximately 1 to 3 minutes of native somatostatin to approximately 90 to 120 minutes after subcutaneous injection in humans [3, 4]. Octreotide received United States Food and Drug Administration approval in 1988 for the symptomatic management of acromegaly and for the control of symptoms associated with metastatic carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas). The long-acting release (LAR) intramuscular depot microsphere formulation (Sandostatin LAR, Novartis) was approved in 1998, enabling once-monthly administration at 10, 20, or 30 milligram doses. An oral octreotide capsule formulation (Mycapssa, Chiasma/Amryt) employing a transient permeability enhancer technology received FDA approval in 2020 for long-term maintenance therapy in acromegaly patients previously responding to injectable somatostatin receptor ligands [5]. The antiproliferative activity of octreotide LAR in metastatic midgut neuroendocrine tumors was established in the PROMID trial (Rinke et al. 2009), a placebo-controlled randomized study demonstrating a median time to tumor progression of 14.3 months versus 6.0 months on placebo (hazard ratio 0.34, p equal to 0.000072) [6]. Pharmacokinetics after subcutaneous administration are characterized by rapid absorption (peak plasma concentration at 25 to 30 minutes), high bioavailability (approximately 100 percent), plasma protein binding of approximately 65 percent predominantly to lipoprotein, hepatobiliary metabolism, and renal elimination of approximately 32 percent of the dose as unchanged drug [3, 4]. The principal adverse effects are gastrointestinal (diarrhea, nausea, abdominal discomfort in 30 to 50 percent of patients, typically self-limiting), cholelithiasis (gallstone or biliary sludge formation in 15 to 30 percent on chronic therapy, attributable to inhibition of cholecystokinin-mediated gallbladder contraction and bile flow), and alterations in glucose homeostasis (suppression of insulin and glucagon secretion producing hyper- or hypoglycemia depending on the metabolic context) [7, 8]. This monograph documents the chemistry, synthesis, and structural pharmacology of octreotide; the somatostatin receptor subtype binding profile and downstream signaling; the comprehensive human pharmacokinetic record across subcutaneous, intramuscular depot, and oral formulations; the clinical evidence base across acromegaly, neuroendocrine tumors, carcinoid syndrome, VIPomas, variceal bleeding, and investigational indications; reconstitution and handling; stack-interaction considerations; the adverse-event and safety record; and a structured comparative assessment of five somatostatin-pathway agents (lanreotide, pasireotide, pegvisomant, paltusotine, lutetium-177 DOTATATE) against octreotide on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1390Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Mecasermin

    Recombinant human insulin-like growth factor 1 (rhIGF-1), a 70-amino-acid single-chain polypeptide with three intramolecular disulfide bonds

    A recombinant analog of endogenous insulin-like growth factor 1 developed at Genentech and commercialized by Tercica (later Ipsen) for the treatment of severe primary IGF-1 deficiency, distinguished from growth hormone replacement by its direct activation of the type 1 IGF-1 receptor and its investigational applications in neuroprotection, neurodevelopmental disorders, and metabolic disease.

    Abstract

    Mecasermin is recombinant human insulin-like growth factor 1 (rhIGF-1), a 70-amino-acid, 7649-dalton non-glycosylated polypeptide produced in Escherichia coli by recombinant DNA technology. The amino acid sequence of mecasermin is identical to that of endogenous human IGF-1, a peptide hormone synthesized principally in the liver under the transcriptional control of growth hormone and serving as the primary mediator of postnatal somatic growth, skeletal maturation, and metabolic homeostasis. Mecasermin is the active pharmaceutical ingredient in Increlex (Ipsen), the only therapy approved by the United States Food and Drug Administration (August 2005, priority review) and by the European Medicines Agency (2007) for the long-term treatment of growth failure in pediatric patients with severe primary insulin-like growth factor 1 deficiency (SPIGFD), a condition most classically represented by Laron syndrome (growth hormone receptor deficiency) and by growth hormone gene deletion with neutralizing antibodies to exogenous growth hormone.

    The mechanism of action is direct agonism of the type 1 IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase structurally homologous to the insulin receptor. Ligand binding activates autophosphorylation of the intracellular kinase domain and recruitment of insulin receptor substrate (IRS) adapter proteins, leading to bifurcated downstream signaling through the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway (metabolic, anti-apoptotic, and translational outcomes) and the Ras/Raf/mitogen-activated protein kinase (MAPK/ERK) pathway (mitogenic, proliferative, and differentiative outcomes). In the growth plate, IGF-1R activation stimulates chondrocyte proliferation and hypertrophy in the proliferative and hypertrophic zones of the epiphyseal cartilage, driving longitudinal bone growth through endochondral ossification. The metabolic actions include stimulation of glucose uptake, amino acid incorporation into protein, fatty acid uptake, and suppression of hepatic glucose output, producing a composite anabolic and mildly hypoglycemic pharmacology.

    Pharmacokinetics following subcutaneous injection are characterized by near-complete bioavailability, a time to peak plasma concentration of approximately 2 hours, and a terminal elimination half-life that is critically dependent on circulating levels of IGF-binding protein 3 (IGFBP-3) and the acid-labile subunit (ALS). In patients with severe primary IGF-1 deficiency, who characteristically have low IGFBP-3 and ALS concentrations, the terminal half-life is approximately 5.8 hours; in healthy individuals with normal binding protein levels, the half-life extends to approximately 19 hours owing to sequestration in the 150-kilodalton ternary complex of IGF-1, IGFBP-3, and ALS. The volume of distribution is approximately 0.257 liters per kilogram. Clearance is inversely proportional to IGFBP-3 concentration and is estimated at 0.04 liters per hour per kilogram at an IGFBP-3 level of 3 micrograms per milliliter. Metabolism is predominantly lysosomal, principally in the liver and kidneys, with degradation to amino acids; less than 0.1 percent of administered drug is excreted unchanged in urine.

    The pivotal clinical evidence base consists of five open-label, single-arm studies in 71 pediatric patients with SPIGFD treated for a mean duration of 3.9 years (274 subject-years of exposure). First-year height velocity increased from a baseline of 2.6 centimeters per year to 8.0 centimeters per year (p less than 0.0001), with sustained growth acceleration over 8 or more years of continuous treatment. The principal adverse event is hypoglycemia, reported in 42 percent of subjects; severe hypoglycemia requiring assistance occurred in 5 subjects, and hypoglycemic seizures or loss of consciousness occurred in 4 subjects. Hypoglycemia is mitigated by administration within 20 minutes of a meal or snack. Other notable adverse events include tonsillar and adenoidal hypertrophy (15 percent), injection site lipohypertrophy, and intracranial hypertension with papilledema (3 subjects). Long-term safety monitoring has not identified an increased incidence of malignancy at approved doses. Investigational applications of mecasermin extend to Rett syndrome (Phase 1, with improvement in apnea and neurobehavioral parameters), amyotrophic lateral sclerosis (negative in controlled trials), and various neuroprotective contexts supported by the neurotrophic properties of IGF-1.

    This monograph reviews the chemistry and recombinant production of mecasermin; the IGF-1R signaling pharmacology in molecular detail; the comprehensive pharmacokinetic record including binding protein dependence; the clinical evidence base across growth failure, neuroprotection, and metabolic indications; sourcing and quality verification for research-grade material; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five alternative growth-promoting or IGF-1-axis compounds against mecasermin on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1422Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Lotiglipron

    Oral nonpeptide small-molecule glucagon-like peptide-1 receptor agonist

    A selective, potent, orally bioavailable small-molecule agonist of the human glucagon-like peptide-1 receptor developed by Pfizer using Sosei Heptares stabilized-receptor technology, advanced through Phase 2 for type 2 diabetes and obesity, and subsequently discontinued owing to hepatic transaminase elevations in a subset of treated participants.

    Abstract

    Lotiglipron (PF-07081532) is an orally administered, nonpeptide, small-molecule agonist of the human glucagon-like peptide-1 receptor (GLP-1R) developed by Pfizer in collaboration with Sosei Heptares. The compound was designed through structure-based drug design leveraging Sosei Heptares proprietary StaR (stabilized receptor) technology platform, which enables crystallographic resolution of G-protein-coupled receptor conformations that are otherwise too unstable for conventional structural characterization. Lotiglipron binds within the transmembrane domain of the GLP-1R, activating the Gs-coupled adenylyl cyclase signaling cascade and increasing intracellular cyclic adenosine monophosphate (cAMP) in a manner functionally analogous to the endogenous incretin peptide GLP-1(7-36)amide but with the pharmacokinetic advantages of oral bioavailability, once-daily dosing without fasting requirements, and a plasma elimination half-life of approximately 21 to 27 hours that supports sustained receptor engagement across the dosing interval.

    The compound entered clinical development in 2021 and was advanced through two Phase 1 multiple-ascending-dose studies (Buckeridge et al. 2024) in 74 participants with type 2 diabetes mellitus (T2D) and 26 participants with obesity without diabetes, demonstrating dose-proportional pharmacokinetics across a 10 to 180 mg once-daily dose range, dose-dependent reductions in glycated hemoglobin (HbA1c) of up to 1.61 percentage points at the 180 mg dose over 42 days, and a safety and tolerability profile consistent with the GLP-1R agonist mechanism class. These findings supported advancement to a Phase 2 dose-ranging study (Amin et al. 2025) in 901 participants (512 with T2D, 389 with obesity), which demonstrated statistically significant reductions in HbA1c of up to 1.44 percentage points (80 mg dose, 16 weeks) and body weight reductions of up to 7.47 percent (200 mg dose, 20 weeks). The Phase 2 study included an open-label semaglutide 14 mg comparator arm; lotiglipron at doses above 20 mg produced HbA1c reductions numerically comparable to or exceeding semaglutide at week 16. However, the Phase 2 study was terminated early following identification of hepatic transaminase elevations (alanine aminotransferase and/or aspartate aminotransferase greater than 3 times the upper limit of normal) in 6.0 to 6.6 percent of lotiglipron-treated participants versus 1.6 percent on placebo, with some individuals reaching elevations greater than 8 times the upper limit of normal. No cases of liver failure, symptomatic hepatitis, or Hy’s law were reported. In June 2023, Pfizer announced discontinuation of the lotiglipron clinical program based on the transaminase signal, pharmacokinetic data from Phase 1 drug-drug-interaction studies suggesting impaired hepatic drug transport or metabolism in a subset of participants, and the inability to prospectively identify at-risk individuals.

    Lotiglipron is structurally characterized as a benzimidazole-piperidinyl-benzodioxole derivative bearing a chloropyridinyl substituent and an oxetanylmethyl group (molecular formula C31H31ClN4O5, molecular weight 575.05 g/mol as free base; CAS 2401892-75-7). The compound is not approved in any jurisdiction and is not in active clinical development. Research-grade lotiglipron is available from multiple chemical suppliers and remains a tool compound for the investigation of small-molecule GLP-1R agonist pharmacology, biased signaling, and hepatic metabolism of the oral GLP-1R agonist class. This monograph reviews the chemistry, synthesis, receptor pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing and handling, stack interactions, adverse events, and a comparative assessment against five oral or nonpeptide GLP-1R agonist candidates on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1409Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • LL-37

    Cathelicidin-derived cationic antimicrobial and immunomodulatory peptide

    The sole human cathelicidin-derived antimicrobial peptide, a 37-residue amphipathic alpha-helical cationic peptide released from the precursor protein hCAP-18 by proteinase 3 cleavage, possessing direct broad-spectrum antimicrobial activity through membrane disruption and pleiotropic immunomodulatory functions mediated by formyl peptide receptor 2, P2X7, and toll-like receptor signaling.

    Abstract

    LL-37, the carboxy-terminal 37-residue peptide of human cationic antimicrobial protein 18 (hCAP-18), is the only cathelicidin-derived antimicrobial peptide identified in the human genome and is a central effector of innate immune defense across epithelial surfaces, wound repair, and inflammatory regulation. The peptide was first identified as FALL-39 by Gudmundsson, Agerberth, and colleagues at the Karolinska Institutet in 1996 through screening of a human bone marrow cDNA library [1], and the mature processed form was subsequently designated LL-37 on the basis of its amino-terminal leucine-leucine sequence and 37-residue length [2]. hCAP-18, the 18-kilodalton holoprotein precursor, is constitutively stored in the specific granules of neutrophils and is released and proteolytically processed by neutrophil-derived proteinase 3 at sites of infection and inflammation to yield the biologically active LL-37 fragment [3]. The peptide adopts an amphipathic alpha-helical conformation in membrane-mimetic environments and exerts direct antimicrobial activity against gram-positive and gram-negative bacteria, enveloped viruses, and fungi through electrostatic interaction with anionic microbial membranes followed by membrane permeabilization and disruption [4, 5]. Beyond direct microbicidal activity, LL-37 functions as a multifunctional immunomodulatory mediator: it signals through formyl peptide receptor 2 (FPR2/ALX) to recruit neutrophils, monocytes, and T cells [6]; it neutralizes bacterial lipopolysaccharide and prevents endotoxin-driven inflammatory cascades [7]; it promotes angiogenesis and wound re-epithelialization through epidermal growth factor receptor transactivation [8]; and it modulates adaptive immune responses through effects on dendritic cell maturation and T helper cell polarization [9]. Expression of hCAP-18/LL-37 is transcriptionally regulated by 1,25-dihydroxyvitamin D3 through a vitamin D response element in the CAMP gene promoter, a mechanism first characterized by Liu et al. (2006) in a landmark demonstration that toll-like receptor activation of human macrophages by Mycobacterium tuberculosis triggers CYP27B1-mediated conversion of 25-hydroxyvitamin D to the active 1,25-dihydroxy form, which then induces cathelicidin expression and intracellular killing of the mycobacterium [10]. This vitamin D-cathelicidin axis has become a major research focus in tuberculosis, respiratory infection, and immunodeficiency. Clinical translation of LL-37 has advanced through Phase I and Phase II trials in chronic wound healing, where topical application of synthetic LL-37 at 0.5 and 1.6 mg/mL produced healing rate constants approximately three- to six-fold greater than placebo in hard-to-heal venous leg ulcers [11], and through a Phase IIb multicenter trial of 148 patients that identified a subgroup benefit in ulcers exceeding 10 cm2 [12]. A randomized trial of recombinant LL-37 delivered via Lactococcus lactis as oral therapy against SARS-CoV-2 Omicron BA.5.1.3 demonstrated significant shortening of viral RNA negative conversion time with early intervention and acceptable safety [13]. The peptide is also implicated in the pathogenesis of rosacea, where aberrant processing of cathelicidin by kallikrein 5 serine protease generates proinflammatory LL-37 fragments in facial skin [14]; in psoriasis, where LL-37 complexed with self-DNA activates plasmacytoid dendritic cells through toll-like receptor 9 [15]; and in cancer biology, where context-dependent pro-tumorigenic and anti-tumorigenic effects have been reported across colorectal, breast, ovarian, and lung malignancies [16, 17]. Pharmacokinetically, the peptide is susceptible to rapid proteolytic degradation in serum with a half-life of minutes to hours depending on protease milieu, limiting systemic bioavailability and driving research toward local and topical delivery, protease-resistant analogs, d-amino acid substitutions, and nanoparticle encapsulation strategies [18, 19]. The compound is commercially available as a synthetic peptide at greater than 95 percent purity from multiple peptide synthesis suppliers. This monograph reviews the chemistry, structure, and processing of LL-37; the molecular pharmacology including direct antimicrobial mechanisms and immunomodulatory receptor signaling; the vitamin D transcriptional axis; preclinical pharmacology across infection, inflammation, and wound healing models; the clinical evidence base in chronic wounds, infectious disease, and dermatologic conditions; reconstitution and handling; stack interactions; adverse events and safety signals including the rosacea and psoriasis pathogenic associations; and a comparative assessment of five alternative antimicrobial and immunomodulatory peptide candidates against LL-37 on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1389Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.